▎ WuXi AppTec content team editor

Regeneron Pharmaceuticals recently announced early data positive results for two research-under-research, innovative bispecific antibodies in phase 1/2 clinical trials

Ovarian cancer is the fifth-largest fatal cancer in women, with an estimated 22,000 newly diagnosed ovarian cancer patients in the United States in 2018, while 14,000 patients died from ovarian cancer

Ubamatamab is a bispecific antibody in research to treat ovarian cancer, targeting CD3 and MUC16, which can promote local T cell activation and anti-tumor activity

▲Ubamatamab profile (Image source: Regeneration Yuan Company official website)

In the dose-escalation trial of umatamab, a total of 78 patients with recurrent ovarian cancer who had received a median 4.

On the other hand, in the dose-escalation test of REGN5093, 6 of the 36 patients with advanced NSCLC with MET variants who received the highest dose of the drug showed partial remission

▲Early clinical trial results of REGN5093 (Source: Regeneration Yuan's official website)

"Bispecific antibodies are an important part of our cancer development pipeline due to their plasticity and potential to treat a wide variety of cancers," said Dr.

▲If you have any business needs, please long press to scan the QR code above, or